MEM 1003
Alternative Names: BAY Z 4406Latest Information Update: 22 Mar 2010
At a glance
- Originator Bayer
- Developer Memory Pharmaceuticals
- Class Antidementias; Dihydropyridines; Neuroprotectants; Small molecules
- Mechanism of Action Calcium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Alzheimer's disease; Bipolar disorders; Mild cognitive impairment; Vascular dementia
Most Recent Events
- 07 Nov 2007 Pharmacodynamics data from a preclinical study in cognitive decline and Alzheimer's disease presented at the 37th Annual Meeting of the Society for Neuroscience (SfN-2007)
- 18 Oct 2007 Final results from a phase IIa clinical trial in patients with Alzheimer's disease added to the adverse events and Alzheimier's Disease therapeutic trials sections
- 11 Apr 2007 Memory Pharmaceuticals completes enrolment in its phase IIa trial for Alzheimer's Disease in the US